NASDAQ:VRCA Verrica Pharmaceuticals (VRCA) Stock Price, News & Analysis $2.74 -0.14 (-4.86%) Closing price 04:00 PM EasternExtended Trading$2.79 +0.05 (+1.79%) As of 04:35 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsInsider TradesNews and TrendsOptions ChainOwnershipSEC Filings About Verrica Pharmaceuticals Stock (NASDAQ:VRCA) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get VRCA alerts:Sign Up Key Stats Today's Range$2.73▼$2.9650-Day Range$2.86▼$4.9152-Week Range$2.73▼$9.82Volume127,031 shsAverage Volume86,267 shsMarket Capitalization$47.07 millionP/E RatioN/ADividend YieldN/APrice Target$12.67Consensus RatingHold Company Overview Verrica Pharmaceuticals is a dermatology-focused biopharmaceutical company that develops and commercializes treatments for skin diseases. The company is based in West Chester, Pennsylvania, and its activities include both marketed products and investigational therapies. Its FDA-approved product, YCANTH, is a topical cantharidin treatment for molluscum contagiosum in adults and children ages 2 and older. The treatment is applied by a healthcare professional. Verrica is also developing therapies for other skin conditions. Its investigational pipeline includes VP-315, a peptide-based treatment being studied for basal cell carcinoma; it has not been approved for use.AI Generated. May Contain Errors. Read More Verrica Pharmaceuticals Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks40th Percentile Overall ScoreVRCA MarketRank™: 1.979180934115 of 5 starsVerrica Pharmaceuticals scored higher than 40% of companies evaluated by MarketBeat, and ranked 627th out of 845 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.6 / 5Analyst RatingHold Consensus RatingVerrica Pharmaceuticals has received a consensus rating of Hold. The company's average rating score is 2.40, and is based on no strong buy ratings, 3 buy ratings, 1 hold rating, and 1 sell rating.Upside PotentialVerrica Pharmaceuticals has a consensus price target of $12.67, representing about 340.4% upside from its current price of $2.88.Amount of Analyst CoverageVerrica Pharmaceuticals has only been the subject of 2 research reports in the past 90 days.Read more about Verrica Pharmaceuticals' stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Verrica Pharmaceuticals are expected to grow in the coming year, from ($2.25) to ($1.70) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Verrica Pharmaceuticals is -1.30, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Verrica Pharmaceuticals is -1.30, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings. Short Interest2.0 / 5Short Interest LevelBearish Percentage of Shares Shorted3.02% of the float of Verrica Pharmaceuticals has been sold short.Short Interest Ratio / Days to CoverVerrica Pharmaceuticals has a short interest ratio ("days to cover") of 4.58.Change versus previous monthShort interest in Verrica Pharmaceuticals has recently increased by 26.89%, indicating that investor sentiment is decreasing significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldVerrica Pharmaceuticals does not currently pay a dividend.Dividend GrowthVerrica Pharmaceuticals does not have a long track record of dividend growth. News and Social Media1.0 / 5News SentimentN/A News SentimentVerrica Pharmaceuticals has a news sentiment score of -0.46. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.40 average news sentiment score of Healthcare companies. Company Ownership1.2 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Verrica Pharmaceuticals insiders have not sold or bought any company stock.Percentage Held by Insiders52.90% of the stock of Verrica Pharmaceuticals is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions42.45% of the stock of Verrica Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Verrica Pharmaceuticals' insider trading history. Receive VRCA Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Verrica Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. VRCA Stock News HeadlinesVerrica (VRCA) Q3 2026 Earnings Call TranscriptNovember 13, 2026 | finance.yahoo.comVerrica Pharmaceuticals Inc. (VRCA) Q3 2026 Earnings Call TranscriptNovember 13, 2026 | seekingalpha.comDrop these 5 stocks before the market opens tomorrow!The Wall Street Journal called it the "$64 trillion question": is a stock market crash on the way? Weiss Ratings' latest research says 2026 could be very rough for some well-known stocks. A major shift now taking shape in the market could hit some of America's most-loved names hard. Weiss analysts have pinpointed five stocks they believe investors should steer clear of while it plays out.November 20 at 1:00 AM | Weiss Ratings (Ad)Verrica Pharmaceuticals Reports Record Q3 YCANTH Revenue, Advances Phase 3 Common Warts Program and Extends Cash RunwayNovember 12, 2026 | quiverquant.comQVerrica Pharmaceuticals Reports Third Quarter 2026 Financial ResultsNovember 12, 2026 | globenewswire.comVerrica Pharmaceuticals to Participate in the Jefferies Global Healthcare Conference in LondonNovember 10, 2026 | finance.yahoo.comVerrica Pharmaceuticals to Report Third Quarter 2026 Financial Results and Provide a Corporate Update on November 12, 2026November 5, 2026 | globenewswire.comVerrica Pharmaceuticals Announces Achievement of Milestones Unlocking Access to the Full $27.5 Million of Non-Dilutive Growth Capital Under Credit FacilityOctober 22, 2026 | globenewswire.comSee More Headlines VRCA Stock Analysis - Frequently Asked Questions How have VRCA shares performed this year? Verrica Pharmaceuticals' stock was trading at $8.31 at the beginning of 2026. Since then, VRCA stock has decreased by 65.4% and is now trading at $2.8760. How were Verrica Pharmaceuticals' earnings last quarter? Verrica Pharmaceuticals Inc. (NASDAQ:VRCA) released its quarterly earnings results on Thursday, November, 12th. The company reported ($0.58) earnings per share for the quarter, missing analysts' consensus estimates of ($0.50) by $0.08. The company had revenue of $6.91 million for the quarter, compared to the consensus estimate of $6.20 million. Verrica Pharmaceuticals had a negative trailing twelve-month return on equity of 423.63% and a negative net margin of 189.23%. Read the conference call transcript. When did Verrica Pharmaceuticals' stock split? Verrica Pharmaceuticals's stock reverse split before market open on Friday, July 25th 2025.A 1-10 reverse split was announced. The number of shares owned by shareholders was adjusted after the market closes on Thursday, July 24th 2025. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split. When did Verrica Pharmaceuticals IPO? Verrica Pharmaceuticals (VRCA) raised $75 million in an initial public offering (IPO) on Friday, June 15th 2018. The company issued 5,000,000 shares at $14.00-$16.00 per share. BofA Merrill Lynch, Jefferies and Cowen served as the underwriters for the IPO. Who are Verrica Pharmaceuticals' major shareholders? Top institutional investors of Verrica Pharmaceuticals include State Street Corp (0.17%) and Fifth Third Bancorp (0.16%). Insiders that own company stock include Paul B Manning, Perceptive Advisors Llc, Jayson Rieger, Ted White, David Zawitz, Christopher G Hayes, Joe Bonaccorso, John J Kirby and Noah L Rosenberg. View institutional ownership trends. How do I buy shares of Verrica Pharmaceuticals? Shares of VRCA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Verrica Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some other companies that Verrica Pharmaceuticals investors own include NVIDIA (NVDA), Tesla (TSLA), Advanced Micro Devices (AMD), Iovance Biotherapeutics (IOVA), Rithm Capital (RITM), Energy Transfer (ET) and NIO (NIO). Company Calendar Last Earnings11/12/2026Today11/20/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Yellow Zone (2m+) 1-Year History Nov 25 Feb 26 May 26 Aug 26 Nov 26 VRCA's financial health is in the Yellow zone, according to TradeSmith. VRCA has been in this zone for over 2 months. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Pharmaceuticals Sub-IndustryPharmaceuticals Current SymbolNASDAQ:VRCA CIK1660334 Webwww.verrica.com Phone(484) 453-3300FaxN/AEmployees76Year Founded2013Price Target and Rating Average Price Target for Verrica Pharmaceuticals$12.67 High Price Target$17.00 Low Price Target$9.00 Potential Upside/Downside+362.3%Consensus RatingHold Rating Score (0-4)2.40 Research Coverage5 Analysts Profitability EPS (Trailing Twelve Months)($2.22) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$17.89 million Net Margins-189.23% Pretax Margin-189.23% Return on Equity-423.63% Return on Assets-102.46% Debt Debt-to-Equity Ratio0.18 Current Ratio1.66 Quick Ratio1.33 Sales & Book Value Annual Sales$35.58 million Price / Sales1.32 Cash FlowN/A Price / Cash FlowN/A Book Value($0.35) per share Price / Book-7.83Miscellaneous Outstanding Shares17,180,000Free Float8,091,000Market Cap$47.07 million OptionableOptionable Beta1.69 Social Links The Best Nuclear Energy Stocks to BuyNuclear energy is entering a new growth cycle as rising power demand, expanding data centers, and renewed policy support bring the sector back into focus. After strong gains in recent years, the most impactful phase of nuclear investment may still be ahead. This report highlights seven nuclear energy stocks positioned across the value chain—combining near-term revenue with long-term upside as next-generation technologies scale. Click the link below to unlock the full list.Get This Free Report This page (NASDAQ:VRCA) was last updated on 11/20/2026 by MarketBeat.com Staff. From Our PartnersPrediction: NVDA will “snap back” on this dateOthers paid $500 for the Snapback Indicator. For Black Friday, Base Camp Trading is offering lifetime access f...Base Camp Trading | SponsoredWhat the hell is going on?Porter Stansberry says President Trump is quietly replacing the U.S. dollar without a vote in Congress, and th...Porter & Company | Sponsored6 Men Secretly Changed America’s Money. Now It’s Happening AgainIn 1910, six powerful men secretly met to lay the groundwork for the Federal Reserve, reshaping America's fina...Banyan Hill Publishing | SponsoredYour book is insideThe "Sucker's Bet" Most New Options Traders Fall For Most people who try options lose money the same way. ...Profits Run | SponsoredBlack Friday Special: Buy These Stocks Before Nov. 30thKeith Kaplan's firm has invested $17 million in its own AI research and tools, and 180,000 people worldwide no...TradeSmith | SponsoredWashington's deadline. Elon's problem.On January 1, 2027, Washington raises the outside-China sourcing requirement for grid battery projects seeking...Behind the Markets | SponsoredThe One-Ticker Retirement BoostA $10,000 investment at its 1998 start would be worth over $630,000 today, roughly 6X the S&P 500 over the sam...The Oxford Club | SponsoredShould I sell? $84 off ends Dec 9A stock you own drops 20%, and you're asking yourself: should I sell? Seeking Alpha Premium gives you a second...Seeking Alpha | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Verrica Pharmaceuticals Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Verrica Pharmaceuticals With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.